Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  The New Zealand medical journal

• Publication date

  2001-03-23

• Fields of study

  Medicine

• Identifiers
  PMID 11346153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic hepatitis C: Interferon retreatment of relapsers. A meta‐analysis of individual patient data

  1999cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• Epidemiology of hepatitis C

  1997cited by this paper
• Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

  1997cited by this paper
• Ribavirin and interferon‐α combination therapy vs interferon‐α alone in the retreatment of chronic hepatitis C: a randomized clinical trial

  1997cited by this paper
• Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

  1996cited by this paper
• COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR.

  1996cited by this paper
• Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.

  1995cited by this paper
• A proposed system for the nomenclature of hepatitis C viral genotypes

  1994cited by this paper
• Serum hepatitis C virus sequences in posttransfusion non-A, non-B hepatitis.

  1991cited by this paper

• THE LEVEL OF CYTOKINES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C, DEPENDING ON THE IL-28B GENOTYPES

  2018cites this paper
• CHRONIC HEPATITIS C WITH SIGNIFICANT MORBIDITY AND END-ORGAN DAMAGE DEVELOPMENT DURING PEG-INTERFERON ALPHA-2A/RIBAVIRIN THERAPY

  2015cites this paper
• Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.

  2013cites this paper
• Ribavirin plus interferon versus interferon for chronic hepatitis C.

  2010cites this paper
• Ribavirin plus interferon versus interferon for chronic hepatitis C.

  2010cites this paper
• Ribavirin monotherapy for chronic hepatitis C.

  2009cites this paper
• Ribavirin monotherapy for chronic hepatitis C.

  2005cites this paper
• Mechanisms of drug resistance to current and future antiviral therapies for hepatitis C virus infection

  2004cites this paper
• Hematopoietic growth factors for acute myelogenous leukemia.

  2004cites this paper
• Hematologic disorders associated with hepatitis C virus infection and their management.

  2003cites this paper
• Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C.

  2003cites this paper
• Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.

  2002cites this paper
• Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide

  2002cites this paper
• Current management of hepatitis C in New Zealand.

  2001cites this paper